<?xml version="1.0" encoding="UTF-8"?>
<p>The second human vaccine that was tested in clinical trials is LeishF3 (
 <xref rid="T1" ref-type="table">Table 1</xref>), composed of the Nucleoside hydrolase NH36 of 
 <italic>Leishmania</italic> (L.) 
 <italic>donovani</italic> (
 <xref rid="B93" ref-type="bibr">93</xref>, 
 <xref rid="B139" ref-type="bibr">139</xref>–
 <xref rid="B145" ref-type="bibr">145</xref>), which is the main antigen of the Leishmune® vaccine (
 <xref rid="B91" ref-type="bibr">91</xref>, 
 <xref rid="B94" ref-type="bibr">94</xref>, 
 <xref rid="B139" ref-type="bibr">139</xref>), and the sterol 24-c-methyltransferase (SMT) from 
 <italic>L</italic>. (L.) 
 <italic>infantum</italic>. The vaccine is adjuvanted by glucopyranosyl lipid A-stable oil-in-water nanoemulsion (GLA-SE) (
 <xref rid="B146" ref-type="bibr">146</xref>, 
 <xref rid="B147" ref-type="bibr">147</xref>). The NH36 was first described in 1993–1996 as the main antigen of the FML complex, against which the antibodies of human patients with VL and anti-FML monoclonal antibodies react (
 <xref rid="B91" ref-type="bibr">91</xref>, 
 <xref rid="B94" ref-type="bibr">94</xref>). Antigen-specific responses of IL-2 and TNF-α were generated in Balb/c and C57 Bl6 mice vaccinated against visceral and cutaneous leishmaniasis (
 <xref rid="B140" ref-type="bibr">140</xref>, 
 <xref rid="B142" ref-type="bibr">142</xref>–
 <xref rid="B144" ref-type="bibr">144</xref>) and in dogs treated against ZVL (
 <xref rid="B148" ref-type="bibr">148</xref>). In addition, the generation of Th1 and Th17 responses against the domains of NH36 was observed in human asymptomatic and cured 
 <italic>L</italic>. (L.) 
 <italic>infantum chagasi</italic>-infected subjects from Brazil (
 <xref rid="B145" ref-type="bibr">145</xref>) and 
 <italic>L</italic>. (L.) 
 <italic>infantum</italic>-infected individuals from Spain (
 <xref rid="B149" ref-type="bibr">149</xref>).
</p>
